Sanvito F, Yao J, Cho N, Raymond C, Telesca D, Pope W
AJNR Am J Neuroradiol. 2024; 46(2):311-320.
PMID: 39242197
PMC: 11878977.
DOI: 10.3174/ajnr.A8475.
Hoggarth A, Muthukumar S, Thomas S, Crowley J, Kiser J, Witcher M
Cancers (Basel). 2024; 16(9).
PMID: 38730666
PMC: 11083317.
DOI: 10.3390/cancers16091715.
Fan H, Luo Y, Gu F, Tian B, Xiong Y, Wu G
Cancer Imaging. 2024; 24(1):36.
PMID: 38486342
PMC: 10938723.
DOI: 10.1186/s40644-024-00682-y.
Barber H, Perks C, Kurian K
Front Neurol. 2024; 15:1358531.
PMID: 38481938
PMC: 10932969.
DOI: 10.3389/fneur.2024.1358531.
Hilario A, Salvador E, Cardenas A, Romero J, Lechuga C, Chen Z
Neuroradiology. 2024; 66(3):317-323.
PMID: 38183424
DOI: 10.1007/s00234-023-03279-7.
Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria.
Douri K, Iorio-Morin C, Mercure-Cyr R, Figueiredo G, Touchette C, Masson-Cote L
Curr Oncol. 2023; 30(11):9382-9391.
PMID: 37999099
PMC: 10670467.
DOI: 10.3390/curroncol30110679.
Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI.
Sanvito F, Raymond C, Cho N, Yao J, Hagiwara A, Orpilla J
Eur Radiol. 2023; 34(5):3087-3101.
PMID: 37882836
PMC: 11045669.
DOI: 10.1007/s00330-023-10215-z.
Differentiating tumour progression from pseudoprogression in glioblastoma patients: a monoexponential, biexponential, and stretched-exponential model-based DWI study.
Liao D, Liu Y, Liu J, Wang D, Liu X
BMC Med Imaging. 2023; 23(1):119.
PMID: 37697237
PMC: 10494379.
DOI: 10.1186/s12880-023-01082-7.
Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series.
Xiang Y, Tang W, Wang J, Wang Z, Bi N
Front Oncol. 2023; 13:1021253.
PMID: 37576884
PMC: 10419187.
DOI: 10.3389/fonc.2023.1021253.
Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity.
Mut M, Adiguzel Z, Cakir-Aktas C, Hanalioglu S, Gungor-Topcu G, Kiyga E
Cancers (Basel). 2023; 15(15).
PMID: 37568598
PMC: 10417317.
DOI: 10.3390/cancers15153782.
Editorial: Untangling post-treatment follow up of brain tumors: the role of neuroimaging.
Anzalone N, Politi L, Caulo M
Front Radiol. 2023; 3:1204517.
PMID: 37492383
PMC: 10364976.
DOI: 10.3389/fradi.2023.1204517.
Charged particle therapy for high-grade gliomas in adults: a systematic review.
Wang Y, Liu R, Zhang Q, Dong M, Wang D, Chen J
Radiat Oncol. 2023; 18(1):29.
PMID: 36755321
PMC: 9906872.
DOI: 10.1186/s13014-022-02187-z.
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Zhao M, Ma H, Cheng P, Yang H, Zhao Y, Han Q
Medicine (Baltimore). 2023; 101(49):e32156.
PMID: 36626518
PMC: 9750629.
DOI: 10.1097/MD.0000000000032156.
A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.
Muthukumar S, Darden J, Crowley J, Witcher M, Kiser J
Int J Mol Sci. 2023; 24(1).
PMID: 36613852
PMC: 9820099.
DOI: 10.3390/ijms24010408.
Performance of F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study.
Yao Y, Tan X, Yin W, Kou Y, Wang X, Jiang X
BMC Med Imaging. 2022; 22(1):226.
PMID: 36566187
PMC: 9789562.
DOI: 10.1186/s12880-022-00952-w.
Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
Liu Y, Chen H, Li G, Zhang J, Yao K, Wu C
Cancer Biol Med. 2022; 19(10).
PMID: 36350001
PMC: 9630524.
DOI: 10.20892/j.issn.2095-3941.2022.0472.
Multimodal MRI-Based Radiomic Nomogram for the Early Differentiation of Recurrence and Pseudoprogression of High-Grade Glioma.
Jing H, Yang F, Peng K, Qin D, He Y, Yang G
Biomed Res Int. 2022; 2022:4667117.
PMID: 36246986
PMC: 9553483.
DOI: 10.1155/2022/4667117.
Glioblastoma - treatment and obstacles.
Cantidio F, Gil G, Queiroz I, Regalin M
Rep Pract Oncol Radiother. 2022; 27(4):744-753.
PMID: 36196416
PMC: 9521695.
DOI: 10.5603/RPOR.a2022.0076.
Radiomics for pseudoprogression prediction in high grade gliomas: added value of MR contrast agent.
Mammadov O, Akkurt B, Musigmann M, Ari A, Blomer D, Kasap D
Heliyon. 2022; 8(8):e10023.
PMID: 35965975
PMC: 9364026.
DOI: 10.1016/j.heliyon.2022.e10023.
The Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in the Differentiation of Pseudoprogression and Recurrence of Intracranial Gliomas.
Jing H, Yan X, Li J, Qin D, Zhang N, Zhang H
Contrast Media Mol Imaging. 2022; 2022:5680522.
PMID: 35935318
PMC: 9337951.
DOI: 10.1155/2022/5680522.